

Prof. Mario Campone's short biography

Mario Campone has been appointed Chief Executive Officer of the Institut de Cancérologie de l'Ouest (ICO) Pays de Loire since June 2016.

He is a member of several professional organizations, including ASCO, EORTC and ESMO. He obtained his PhD from the University of Nantes. In addition, he holds an MLA in cell biology and a PhD in life sciences and health from the university. Part of his training was at the Beatson Institute in Glasgow, UK. He is currently a medical oncology at the ICO. He is a professor of medical oncology at the University of Angers. He has joined the team-8 led by the Nantes-Angers cancer and immunology research center (UMR-1232) of Dr Juin, Inserm. The aim of his research is to identify how aberrant survival contributes to tumor escape and promotes resistance to conventional and targeted therapies, and to identify new targets for innovative treatments.

He has been involved in clinical research since 2003 as a coordinator and principal investigator in 100 clinical trials investigating the therapeutic expertise of new agents in breast disease.

He is author or co-author of more than 334 publications in peer-reviewed journals in the field of cancer and molecular biology. He has been awarded two national clinical research hospital programs and an Inca grant in translational research. He is co-owner of 3 patents.

He was President of the Medical Commission of the René Gauducheau Cancer Center from 2005 to 2012. At the national level, he was president of the early study group (2012-2016) and vice-president of the personalized medicine group of UNICANCER (2015-2019). He is an expert at Inca and was a member of the National Agency for the Safety of Medicines (2007-2017).

Since November 2015, new Scientific Director of Cancéropôle Grand Ouest (Bretagne Pays de la Loire and Région Centre). He has been the spokesperson for the Cancéropôles conference since 2016.

In November 2016, he became president of the Loire-Atlantique and Vendée Cancer Registry.

Since 2018, he is vice-president of the SIRIC 'Iliad' labelled by the INCA (integrated cancer research sites) and of CLIP 2.

Since October 2016, he has been a member of the Unicancer board and became Deputy President of Unicancer in October 2019.